Mood Disorders

Zuranolone Safety and Tolerability in Adults with Postpartum Depression: Analyses from SKYLARK, a 50 mg Placebo-Controlled Study

In the SKYLARK Study, zuranolone 50 mg was generally well tolerated in adults with postpartum depression; treatment-emergent adverse events (TEAEs) led to zuranolone dose reduction and di...

10/26/2023

Understanding the Real-World Prescription Patterns and Impact of Atypical Antipsychotic Augmentation Timing on Healthcare Cost in Adult Major Depressive Disorder in the United States: A Systematic Literature Review

This study examined the utilization pattern of augmentation with atypical antipsychotics after partial or no response to antidepressants in patients with MDD. The antidepressant prescript...

10/26/2023

Unique Features of the Rapid Mood Screener Enable Detection of Bipolar I Disorder in a Primary Care Practice

The Rapid Mood Screener (RMS) is a self-administered screening tool to help differentiate bipolar I disorder from major depressive disorder. Cases were identified from a primary care sett...

10/26/2023

Understanding the Experiences of Patients With Major Depressive Disorder Treated With Zuranolone: Qualitative Interviews With Participants From the Open-Label SHORELINE Study

Researchers conducted qualitative interviews to understand patients’ experiences with and perceptions of zuranolone, an oral, investigational, once-daily, 14-day treatment course in clini...

10/26/2023

Time Dynamics of Adverse Events of Interest Occurring with Esketamine Nasal Spray and Quetiapine Extended Release: Results from the ESCAPE‑TRD Phase IIIb Trial

This safety analysis evaluated the duration of treatment-emergent adverse events (TEAEs) reported for esketamine nasal spray (ESK-NS) versus quetiapine extended release (QTP-XR) in patien...

10/26/2023

The Rapid Mood Screener (RMS) for Bipolar I Disorder: Study Design for a Confirmatory Study Evaluating Performance in Real-World Settings

This large, cross-sectional, observational study will be conducted in a sample reflecting bipolar I disorder prevalence in real-world settings to confirm the performance of the Rapid Mood...

10/26/2023

Safety and Tolerability of Zuranolone 50 mg in Patients with Major Depressive Disorder: Results from the Phase 3 WATERFALL and CORAL Studies

Zuranolone 50 mg initiated alone (WATERFALL Study) or co-initiated with a standard-of-care antidepressant (CORAL Study) was well-tolerated in adults with major depressive disorder. In WAT...

10/26/2023

Real-World Observational Study of Implementation and Evaluation of the Pathway Platform: A Digitally Enabled Care Pathway to Improve Depression Management in Primary Care

The Pathway Platform supports MBC for patients with MDD by integrating a patient-facing app with EHR. This real-world Pathway Platform implementation study in primary care demonstrated si...

10/26/2023

Real-World Safety Profile of Esketamine Nasal Spray During the First 12 Treatment Sessions: An Analysis at 46 Months After Approval in the United States

This research examined real-world safety data for esketamine nasal spray (ESK) for the first 46 months after product approval, with a focus on adverse events (AEs) of interest (i.e., seda...

10/26/2023

Qualitative Study to Assess the Patient Perspective on Anhedonia Symptoms and Impacts in Major Depressive Disorder

This qualitative research study assessed the patient experience of anhedonia and its impacts among patients with MDD. Semi-structured concept elicitation interviews were conducted with 1...

10/26/2023